Display options
Share it on

Nephron Extra. 2017 Apr 07;7(1):33-41. doi: 10.1159/000458711. eCollection 2017.

MicroRNA-155 and Anti-Müllerian Hormone: New Potential Markers of Subfertility in Men with Chronic Kidney Disease.

Nephron extra

Dag Eckersten, Christos Tsatsanis, Aleksander Giwercman, Laila Bruun, Mats Pihlsgård, Anders Christensson

Affiliations

  1. Department of Nephrology, Lund University, Skåne University Hospital, Malmö, Sweden.
  2. Department of Clinical Chemistry, School of Medicine, University of Crete, Heraklion, Crete, Greece.
  3. Molecular Reproductive Medicine, Department of Translational Medicine, Lund University, Malmö, Sweden.
  4. Department of Geriatrics, Lund University, Skåne University Hospital, Malmö, Sweden.

PMID: 28553316 PMCID: PMC5423313 DOI: 10.1159/000458711

Abstract

BACKGROUND/AIMS: Men with terminal renal failure are often infertile. Anti-müllerian hormone (AMH), a marker of Sertoli cell function, is decreased among men with chronic kidney disease (CKD). Recently, a microRNA, miR-155, has been shown to be a potential marker for subfertility. We studied miR-155 and semen parameters in patients with CKD who were not yet on dialysis. We also aimed to study possible associations between AMH, miR-155, and semen parameters to evaluate them as markers of fertility.

METHODS: Thirty male patients with CKD 1-4 as well as 18 healthy controls were enrolled.

RESULTS: Serum levels of miR-155 were significantly higher among men with CKD stages 1-2 (4.51 ± 3.81 [

CONCLUSIONS: We conclude that men with stage 3-4 CKD had lower sperm concentrations than healthy fertile men and that increased serum miR-155 in men with stage 1-4 CKD was associated with semen parameters that indicate subfertility. Low AMH levels were associated with a low percentage of the total number of motile sperm cells. miR-155 and AMH may be potential markers of subfertility in men with CKD.

Keywords: Chronic kidney disease; Fertility; Hemodialysis

References

  1. BMC Nephrol. 2012 Nov 27;13:159 - PubMed
  2. Gynecol Endocrinol. 2008 Mar;24(3):158-60 - PubMed
  3. Arch Androl. 1999 Jan-Feb;42(1):9-20 - PubMed
  4. Am J Med. 1980 Apr;68(4):522-30 - PubMed
  5. Asian J Androl. 2011 Nov;13(6):856-61 - PubMed
  6. Hum Reprod. 2004 Oct;19(10):2277-82 - PubMed
  7. N Engl J Med. 1977 Jun 2;296(22):1245-9 - PubMed
  8. Scand J Clin Lab Invest. 1972 Nov;30(3):271-4 - PubMed
  9. Nat Rev Immunol. 2011 Mar;11(3):163-75 - PubMed
  10. J Clin Endocrinol Metab. 1976 Dec;43(6):1370-7 - PubMed
  11. Hum Reprod. 2015 Apr;30(4):853-60 - PubMed
  12. J Lab Clin Med. 1984 Dec;104(6):955-61 - PubMed
  13. J Immunol. 2015 Dec 15;195(12):5750-61 - PubMed
  14. PLoS One. 2013 Apr 18;8(4):e61466 - PubMed
  15. Br J Urol. 1996 Oct;78(4):635-8 - PubMed
  16. Fertil Steril. 2007 Aug;88(2):516-8 - PubMed
  17. Indian J Clin Biochem. 2013 Oct;28(4):390-5 - PubMed
  18. Int J Endocrinol. 2015;2015:321901 - PubMed
  19. Andrology. 2015 Nov;3(6):1160-4 - PubMed
  20. Asian J Androl. 2015 Jan-Feb;17(1):149-53 - PubMed
  21. Proc Natl Acad Sci U S A. 2012 Jun 12;109(24):9517-22 - PubMed
  22. J Clin Endocrinol Metab. 2004 Jun;89(6):2873-9 - PubMed
  23. Scand J Clin Lab Invest. 1997 Oct;57(6):463-70 - PubMed
  24. BJU Int. 2003 Aug;92(3):281-3 - PubMed
  25. Semin Dial. 2010 Sep-Oct;23(5):498-509 - PubMed
  26. Int J Androl. 2002 Oct;25(5):306-11 - PubMed
  27. Postgrad Med J. 2006 Oct;82(972):693-6 - PubMed
  28. Methods Cell Sci. 2000;22(2-3):169-89 - PubMed
  29. Clin Biochem. 2013 Jul;46(10-11):846-60 - PubMed

Publication Types